Alzheimer's Clinical Trial Consortium (ACTC) Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2020
NCT04468659
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Alzheimer's Clinical Trial Consortium (ACTC) | Alzheimer's Clinical Trials Consortium

Active Ingredients

Drugs in Phase 3 Trials (1)

ban2401 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Amyloidosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1